Post by arfanho7 on Feb 27, 2024 11:11:08 GMT
At the minute mark Lassiter reiterates the urgent need to present an immediate alternative to coal. The thing that makes this question pressing is that unless you give the Chinese and Indians a clearly perceived alternative to coal that means cheap enough and scalable enough probably by the mid s then the coal plants will have already been built. The carbon will already be in the air. And it will be too late.
Read more about Lassiter s views on nuclear power and the funding of new energy sources The Case for Combating Climate Change with Nuclear Power and Fracking We Need a Miracle. New Nuclear Might Hungary Phone Number Provide it. Venture Capital s Disconnect with Clean Tech New Medical Devices Get To Patients Too Slowly by Michael Blanding The FDA has streamlined drug testing to ensure new therapies come to market quickly. But when it comes to life giving medical devices approvals seem unnecessarily slow according to research by Ariel Dora Stern.
While the US Food and Drug Administration has chiseled away pharmaceutical review times over the years to speed innovative drugs to market the opposite seems to have occurred in the agency s approval of medical devices. Instead of speeding innovative first mover products to market devices such as implantable defibrillators or transcatheter heart valves the FDA s regulatory approval process appears to delay those approvals which in turn adds to development costs borne by device manufacturers according to Innovation under Regulatory Uncertainty Evidence from Medical Technology pdf a new working paper by Ariel Dora Stern an assistant professor at Harvard Business School.
Read more about Lassiter s views on nuclear power and the funding of new energy sources The Case for Combating Climate Change with Nuclear Power and Fracking We Need a Miracle. New Nuclear Might Hungary Phone Number Provide it. Venture Capital s Disconnect with Clean Tech New Medical Devices Get To Patients Too Slowly by Michael Blanding The FDA has streamlined drug testing to ensure new therapies come to market quickly. But when it comes to life giving medical devices approvals seem unnecessarily slow according to research by Ariel Dora Stern.
While the US Food and Drug Administration has chiseled away pharmaceutical review times over the years to speed innovative drugs to market the opposite seems to have occurred in the agency s approval of medical devices. Instead of speeding innovative first mover products to market devices such as implantable defibrillators or transcatheter heart valves the FDA s regulatory approval process appears to delay those approvals which in turn adds to development costs borne by device manufacturers according to Innovation under Regulatory Uncertainty Evidence from Medical Technology pdf a new working paper by Ariel Dora Stern an assistant professor at Harvard Business School.
